From: Clinical management of gastric cancer: results of a multicentre survey
Adjuvant practice | Recommendation of the Guidelines | Oncological surgeons | Medical oncologists | Radiation oncologists | p | |||
---|---|---|---|---|---|---|---|---|
 |  | N | % | N | % | N | % |  |
moderately differentiated adenocarcinoma pT4N0M0 after gastrectomy | postoperative chemoradiation | Â | Â | Â | Â | Â | Â | 0.007 |
observe without postoperative treatment | Â | 19 | 18.81 | 0 | 0 | 0 | 0 | Â |
postoperative chemotherapy | Â | 57 | 56.44 | 102 | 63.35 | 26 | 27.08 | Â |
postoperative radiotherapy | Â | 0 | 0 | 0 | 0 | 7 | 7.29 | Â |
postoperative chemoradiation | Â | 25 | 24.75 | 59 | 36.65 | 63 | 65.63 | Â |
moderately differentiated adenocarcinoma pT4N0M0 after gastrectomy | Systemic chemotherpy | Â | Â | Â | Â | Â | Â | < 0.001 |
Systemic chemotherapy | Â | 73 | 72.28 | 89 | 55.28 | 75 | 78.13 | Â |
Intraperitoneal chemotherapy(IP) | Â | 0 | 0 | 0 | 0 | 0 | 0 | Â |
Systemic chemotherapy+IP | Â | 28 | 27.72 | 72 | 44.72 | 21 | 21.88 | Â |
Other | Â | 0 | 0 | 0 | 0 | 0 | 0 | Â |
moderately differentiated adenocarcinoma invaded muscularis and vascular without metastasis in the 16 removed regional lymph nodes | postoperative chemotherapy | Â | Â | Â | Â | Â | Â | 0.044 |
observe without postoperative treatment | Â | 41 | 40.59 | 37 | 22.98 | 26 | 27.08 | Â |
postoperative chemotherapy | Â | 46 | 45.54 | 73 | 45.34 | 38 | 39.58 | Â |
postoperative radiotherapy | Â | 0 | 0 | 0 | 0 | 13 | 13.54 | Â |
postoperative chemoradiation | Â | 14 | 13.86 | 51 | 31.68 | 19 | 19.79 | Â |
other | Â | 0 | 0 | 0 | 0 | 0 | 0 | Â |
poor differentiated adenocarcinoma invaded muscularis without metastasis in the 16 removed regional lymph nodes | postoperative chemotherapy | Â | Â | Â | Â | Â | Â | 0.053 |
observe without postoperative treatment | Â | 52 | 51.49 | 21 | 13.04 | 17 | 17.71 | Â |
postoperative chemotherapy | Â | 43 | 42.57 | 140 | 86.96 | 58 | 60.42 | Â |
postoperative radiotherapy | Â | 3 | 2.97 | 0 | 0 | 0 | 0 | Â |
postoperative chemoradiation | Â | 3 | 2.97 | 0 | 0 | 21 | 21.88 | Â |
other | Â | 0 | 0 | 0 | 0 | 0 | 0 | Â |
well differentiated adenocarcinoma invaded muscularis without metastasis in the 6 removed regional lymph nodes | observe without postoperative treatment | Â | Â | Â | Â | Â | Â | 0.020 |
observe without postoperative treatment | Â | 29 | 28.71 | 68 | 42.24 | 36 | 37.50 | Â |
postoperative chemotherapy | Â | 66 | 65.35 | 61 | 37.89 | 36 | 37.50 | Â |
postoperative radiotherapy | Â | 0 | 0 | 0 | 0 | 5 | 5.21 | Â |
postoperative chemoradiation | Â | 6 | 5.94 | 32 | 19.88 | 19 | 19.79 | Â |
other | Â | 0 | 0 | 0 | 0 | 0 | 0 | Â |
when begin adjuvant chemotherapy after gastrectomy | NA | Â | Â | Â | Â | Â | Â | 0.233 |
1-2 w | Â | 13 | 12.87 | 28 | 17.39 | 11 | 11.46 | Â |
3-4 w | Â | 82 | 81.19 | 133 | 82.61 | 79 | 82.29 | Â |
5-6 w | Â | 4 | 3.96 | 0 | 0 | 6 | 6.25 | Â |
≥ 6 w |  | 2 | 1.98 | 0 | 0 | 0 | 0 |  |
regimen usually used in adjuvant setting (without neoadjuvant chemotherapy) | CF(DDP+5FU) or fluoropyrimidine(5Fu or Capecitabine) | Â | Â | Â | Â | Â | Â | 0.383 |
CF(DDP+5FU) | Â | 18 | 17.82 | 21 | 13.04 | 12 | 12.50 | Â |
ECF(EPI+DDP+5FU) | Â | 12 | 11.88 | 25 | 15.53 | 7 | 7.29 | Â |
fluoropyrimidine(5Fu or Capecitabine) | Â | 12 | 11.88 | 11 | 6.83 | 11 | 11.46 | Â |
oxaliplatin based regimen | Â | 34 | 33.66 | 69 | 42.86 | 44 | 45.83 | Â |
irinotecan based regimen | Â | 20 | 19.80 | 8 | 4.97 | 9 | 9.38 | Â |
paclitaxel or docetaxel based regimen | Â | 5 | 4.95 | 24 | 14.91 | 8 | 8.33 | Â |
combination of above or other | Â | 0 | 0 | 3 | 1.86 | 5 | 5.21 | Â |
how long adjuvant chemtherapy last | NA | Â | Â | Â | Â | Â | Â | 0.220 |
1-3 m | Â | 11 | 10.89 | 2 | 1.24 | 11 | 11.46 | Â |
4-6 m | Â | 71 | 70.30 | 144 | 89.44 | 63 | 65.63 | Â |
7-9 m | Â | 7 | 6.93 | 3 | 1.86 | 7 | 7.29 | Â |
10-12 m | Â | 5 | 4.95 | 5 | 3.11 | 8 | 8.33 | Â |
≥ 12 m |  | 3 | 2.97 | 4 | 2.48 | 7 | 7.29 |  |
3-6 m in the first year, then 2-3 m annually for 2-3 y | Â | 4 | 3.96 | 3 | 1.86 | 0 | 0 | Â |
other | Â | 0 | 0 | 0 | 0 | 0 | 0 | Â |